BDTX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

BDTX ▲ +28.70% at T+20d

NEUTRAL call ✓ call won +28.70% · α vs SPY +24.40% · entry $2.23 → $2.87

Next anchor: T+60d in 5h

Last close $1.85 (close Jun 8) · -17.04% from $2.23 entry

Entry anchored
Mar 16, 03:59 PM ET
via Databento tick

T+1d

-2.69%

call -2.69% · α -1.29%

$2.17

settled 3mo ago

T+5d

-4.04%

call -4.04% · α -1.38%

$2.14

settled 3mo ago

T+20d

+28.70%

call +28.70% · α +24.40%

$2.87

settled 8w ago

T+60d

—

call — · α —

—

in 5h

Price Chart

Loading chart...

Executive Summary

Black Diamond Therapeutics reported financial results for Q4 and full year 2025, highlighted by a significant improvement in net income due to a $70M one-time license revenue and reduced R&D and G&A expenses. The company has $128.7M in cash, sufficient to fund operations into H2 2028, and expects key clinical updates on silevertinib in Q2 2026 for NSCLC and GBM trials.

Key Financial Metrics

Revenue

$70.0M

EPS

$0.39

Actionable Insight

The $70M license revenue is non-recurring, so future performance hinges on clinical progress of silevertinib. Traders should monitor upcoming data readouts in Q2 2026 as key value inflection points. The extended cash runway reduces near-term dilution risk.

Key Facts

Reported $70 million in license revenue in 2025 (vs. $0 in 2024), driving a swing from a $69.7M net loss to $22.4M net income.
R&D expenses decreased to $33.6M in 2025 from $51.3M in 2024 due to workforce efficiencies and outlicensing of BDTX-4933.
G&A expenses fell to $16.6M in 2025 from $27.5M in 2024 due to operational restructuring.
Cash, cash equivalents, and investments totaled $128.7M as of December 31, 2025, up from $98.6M in 2024.
Company expects to present updated Phase 2 data for silevertinib in NSCLC (including DOR and PFS) and initiate a randomized Phase 2 GBM trial in Q2 2026.

Financial Impact

One-time $70M license revenue significantly improved 2025 financials; operating expenses reduced by ~$21M YoY. Cash runway extended to mid-2028.

revenuenet_incomecash_positionoperating_expenses

Risk Factors

Revenue is driven entirely by a one-time license payment; no recurring product or royalty revenue yet.
Clinical development risk for silevertinib in NSCLC and GBM remains high, with pivotal trials not yet initiated.
Stock is micro-cap ($121M market cap), making it highly volatile and sensitive to trial outcomes.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3256691

5 reports for BDTX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+1▲ +6.35%Apr 21, 2026

Filters

Reports for BDTX — sortable, filterable
	Type				Now
May 21, 2026 19d ago	8-K BULLISH ★ 7/10	$2.28 $2.26	▼ −0.88%	▼ −2.55%	$1.85 (−18.86%)
May 21, 2026 19d ago	Press Release BULLISH ★ 8/10	$2.28 $2.26	▼ −0.88%	▼ −2.55%	$1.85 (−18.86%)
May 7, 2026 4w ago	8-K NEUTRAL ★ 4/10	$2.72 $2.86	▲ +5.15%	▲ +3.64%	$1.85 (−31.99%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$3.15 $2.70	▼ −14.29%	▼ −15.37%	$1.85 (−41.27%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.23 $2.14	▼ −4.04%	▼ −1.38%	$1.85 (−17.04%)

US Market Status

Market Closed — Opens in 6h 56m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access